Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?
暂无分享,去创建一个
C. Rudin | J. Minna | L. Byers | M. Pietanza
[1] S. Rodig,et al. Myc protein expression correlates with MYC amplification in small‐cell lung carcinoma , 2015, Histopathology.
[2] Aurélien Marabelle,et al. Immune Checkpoint Modulation for Non–Small Cell Lung Cancer , 2015, Clinical Cancer Research.
[3] A. Shaw,et al. Therapeutic Targeting of Anaplastic Lymphoma Kinase in Lung Cancer: A Paradigm for Precision Cancer Medicine , 2015, Clinical Cancer Research.
[4] P. Hammerman,et al. Squamous Cell Lung Cancer: From Tumor Genomics to Cancer Therapeutics , 2015, Clinical Cancer Research.
[5] Gregory Riely,et al. EGFR: The Paradigm of an Oncogene-Driven Lung Cancer , 2015, Clinical Cancer Research.
[6] M. Fischer,et al. Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency , 2015, Clinical Cancer Research.
[7] Martin L. Miller,et al. Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer , 2015, Science.
[8] T. Jacks,et al. The Comparative Pathology of Genetically Engineered Mouse Models for Neuroendocrine Carcinomas of the Lung , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[9] E. Vokes,et al. Chemotherapy With or Without Maintenance Sunitinib for Untreated Extensive-Stage Small-Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase II Study-CALGB 30504 (Alliance). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] F. Cappuzzo,et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. , 2015, The Lancet. Oncology.
[11] Roman K. Thomas,et al. PD-L1 expression in small cell neuroendocrine carcinomas. , 2015, European journal of cancer.
[12] V. Devita,et al. DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of Oncology , 2015 .
[13] H. Kohrt,et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients , 2014, Nature.
[14] Tao Wang,et al. ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers , 2014, Proceedings of the National Academy of Sciences.
[15] C. Sima,et al. 1229PDSMOKING HISTORY AND RESPONSE TO NIVOLUMAB IN PATIENTS WITH ADVANCED NSCLCS. , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] Steven J. M. Jones,et al. Comprehensive molecular profiling of lung adenocarcinoma , 2014, Nature.
[17] Mahmood Ayub,et al. Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer , 2014, Nature Medicine.
[18] M. Ladanyi,et al. Small-Cell Lung Cancers in Patients Who Never Smoked Cigarettes , 2014, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[19] D. Matei,et al. Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients. , 2014 .
[20] J. Welsh,et al. Progress in the management of limited‐stage small cell lung cancer , 2014, Cancer.
[21] C. Rudin,et al. MYC, MAX, and small cell lung cancer. , 2014, Cancer discovery.
[22] A. McKenna,et al. Genetic and Clonal Dissection of Murine Small Cell Lung Carcinoma Progression by Genome Sequencing , 2014, Cell.
[23] Sherry X. Yang,et al. Targeting notch signaling pathway in cancer: clinical development advances and challenges. , 2014, Pharmacology & therapeutics.
[24] Nicholas T. Ingolia,et al. PTEN Is a Potent Suppressor of Small Cell Lung Cancer , 2014, Molecular Cancer Research.
[25] A. Butte,et al. A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumors. , 2013, Cancer discovery.
[26] Jing Wang,et al. Teaching an old dog new tricks: drug repositioning in small cell lung cancer. , 2013, Cancer discovery.
[27] Ying Feng,et al. Proteomic Markers of DNA Repair and PI3K Pathway Activation Predict Response to the PARP Inhibitor BMN 673 in Small Cell Lung Cancer , 2013, Clinical Cancer Research.
[28] M. Fischer,et al. Small molecule inhibitors of aurora-a induce proteasomal degradation of N-myc in childhood neuroblastoma. , 2013, Cancer cell.
[29] B. Teicher. Perspective: Opportunities in recalcitrant, rare and neglected tumors , 2013, Oncology reports.
[30] P. Chuang,et al. Functional characterization of pulmonary neuroendocrine cells in lung development, injury, and tumorigenesis , 2012, Proceedings of the National Academy of Sciences.
[31] Herbert Waldmann,et al. A framework for identification of actionable cancer genome dependencies in small cell lung cancer , 2012, Proceedings of the National Academy of Sciences.
[32] Steven J. M. Jones,et al. Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.
[33] K. Cibulskis,et al. Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer , 2012, Nature Genetics.
[34] Robert Gentleman,et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer , 2012, Nature Genetics.
[35] Michael Peyton,et al. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. , 2012, Cancer discovery.
[36] H. Serve,et al. Deacetylase inhibitors modulate proliferation and self-renewal properties of leukemic stem and progenitor cells , 2012, Cell cycle.
[37] G. Giaccone,et al. Phase II Study of Single-Agent Navitoclax (ABT-263) and Biomarker Correlates in Patients with Relapsed Small Cell Lung Cancer , 2012, Clinical Cancer Research.
[38] R. Herbst,et al. Small-cell lung cancer: prognostic factors and changing treatment over 15 years. , 2012, Clinical lung cancer.
[39] Peter Dirks,et al. Cancer stem cells: an evolving concept , 2012, Nature Reviews Cancer.
[40] Paul A. Rejto,et al. An Integrated Genomic Approach to Identify Predictive Biomarkers of Response to the Aurora Kinase Inhibitor PF-03814735 , 2012, Molecular Cancer Therapeutics.
[41] C. Rudin,et al. A phase II study of obatoclax mesylate, a Bcl-2 antagonist, plus topotecan in relapsed small cell lung cancer. , 2011, Lung cancer.
[42] E. Vokes,et al. Cisplatin, irinotecan, and bevacizumab for untreated extensive-stage small-cell lung cancer: CALGB 30306, a phase II study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] Roman K. Thomas,et al. A crucial requirement for Hedgehog signaling in small cell lung cancer , 2011, Nature Medicine.
[44] P. Sandy,et al. Targeting MYC dependence in cancer by inhibiting BET bromodomains , 2011, Proceedings of the National Academy of Sciences.
[45] C. D. Salcido,et al. Schedule-dependent synergy of histone deacetylase inhibitors with DNA damaging agents in small cell lung cancer , 2011, Cell cycle.
[46] C. Gatsonis,et al. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening , 2012 .
[47] S. An,et al. Histone Deacetylase Inhibitors Sensitize Human Non-small Cell Lung Cancer Cells to Ionizing Radiation Through Acetyl p53-Mediated c-myc Down-Regulation , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[48] A. Berns,et al. Cell of origin of small cell lung cancer: inactivation of Trp53 and Rb1 in distinct cell types of adult mouse lung. , 2011, Cancer cell.
[49] A. Berns,et al. A functional role for tumor cell heterogeneity in a mouse model of small cell lung cancer. , 2011, Cancer cell.
[50] S. Dacic,et al. Phase II Study of Everolimus (RAD001) in Previously Treated Small Cell Lung Cancer , 2010, Clinical Cancer Research.
[51] Thomas K. Schulz,et al. Sorafenib in Platinum-Treated Patients with Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group (SWOG 0435) Phase II Trial , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[52] Mark A. Hall,et al. Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant state. , 2010, Blood.
[53] R. Govindan,et al. Phase II Study of Cediranib (AZD 2171), an Inhibitor of the Vascular Endothelial Growth Factor Receptor, for Second-Line Therapy of Small Cell Lung Cancer (National Cancer Institute #7097) , 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[54] A. Sweet-Cordero,et al. Loss of p130 accelerates tumor development in a mouse model for human small-cell lung carcinoma. , 2010, Cancer research.
[55] E. Birney,et al. A small cell lung cancer genome reports complex tobacco exposure signatures , 2009, Nature.
[56] D. Moore,et al. Phase II study of cisplatin plus etoposide and bevacizumab for previously untreated, extensive-stage small-cell lung cancer: Eastern Cooperative Oncology Group Study E3501. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[57] A. Hackshaw,et al. Anti-angiogenic therapy using thalidomide combined with chemotherapy in small cell lung cancer: a randomized, double-blind, placebo-controlled trial. , 2009, Journal of the National Cancer Institute.
[58] J. Hainsworth,et al. Phase II Trial of Irinotecan, Carboplatin, and Bevacizumab in the Treatment of Patients with Extensive-Stage Small-Cell Lung Cancer , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[59] A. Desideri,et al. Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis , 2009, Molecular Cancer Therapeutics.
[60] Giovanni Parmigiani,et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. , 2009, Cancer research.
[61] F. Gejyo,et al. Reciprocal CD4+T Cell Balance of Effector CD62LlowCD4+and CD62LhighCD25+CD4+Regulatory T Cells in Small Cell Lung Cancer Reflects Disease Stage. , 2009, Asian Test Symposium.
[62] M. Brock,et al. Achaete-scute complex homologue 1 regulates tumor-initiating capacity in human small cell lung cancer. , 2009, Cancer research.
[63] S. Ou,et al. Prognostic Factors for Survival in Extensive Stage Small Cell Lung Cancer (ED-SCLC): The Importance of Smoking History, Socioeconomic and Marital Statuses, and Ethnicity , 2009, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[64] Junjie Chen,et al. Aurora A Is Essential for Early Embryonic Development and Tumor Suppression* , 2008, Journal of Biological Chemistry.
[65] F. Gejyo,et al. Reciprocal CD4 T-Cell Balance of Effector CD62L CD4 and CD62LCD25 CD4 Regulatory TCells in Small Cell Lung Cancer Reflects Disease Stage , 2008 .
[66] F. Rojo,et al. Genetic changes in small cell lung carcinoma , 2008, Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico.
[67] S. Lens,et al. The Aurora kinase family in cell division and cancer. , 2008, Biochimica et biophysica acta.
[68] D. N. Watkins,et al. Cancer stem cells and the ontogeny of lung cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[69] C. Rudin,et al. Randomized phase II Study of carboplatin and etoposide with or without the bcl-2 antisense oligonucleotide oblimersen for extensive-stage small-cell lung cancer: CALGB 30103. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] M. Hidalgo,et al. A Randomized, Phase II Trial of Two Dose Levels of Temsirolimus (CCI-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding or Stable Disease after Induction Chemotherapy: A Trial of the Eastern Cooperative Oncology Group (E1500) , 2007, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[71] L. Seymour,et al. Phase II study of vandetanib or placebo in small-cell lung cancer patients after complete or partial response to induction chemotherapy with or without radiation therapy: National Cancer Institute of Canada Clinical Trials Group Study BR.20. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[72] A. Turrisi,et al. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). , 2007, Chest.
[73] J. Pujol,et al. Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[74] L. Collette,et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. , 2007, The New England journal of medicine.
[75] J. von Pawel,et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[76] Peter A. Jones,et al. The Epigenomics of Cancer , 2007, Cell.
[77] Lee L. Rubin,et al. Targeting the Hedgehog pathway in cancer , 2006, Nature Reviews Drug Discovery.
[78] T. Ciuleanu,et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[79] J. Crowley,et al. Bortezomib (PS-341) in Relapsed or Refractory Extensive Stage Small Cell Lung Cancer: A Southwest Oncology Group Phase II Trial (S0327) , 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[80] A. Hackshaw,et al. Early compared with late radiotherapy in combined modality treatment for limited disease small-cell lung cancer: a London Lung Cancer Group multicenter randomized clinical trial and meta-analysis. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[81] Hongye Liu,et al. Predicting Survival within the Lung Cancer Histopathological Hierarchy Using a Multi-Scale Genomic Model of Development , 2006, PLoS medicine.
[82] P. Lambin,et al. Systematic review and meta-analysis of randomised, controlled trials of the timing of chest radiotherapy in patients with limited-stage, small-cell lung cancer. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.
[83] P. Lambin,et al. Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[84] Y. Bang,et al. Histone Deacetylase Inhibitors for Cancer Therapy , 2006, Epigenetics.
[85] Y. Yatabe,et al. ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features. , 2005, Cancer research.
[86] J. Jett,et al. A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[87] K. Altundag,et al. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c‐kit protein: A phase II clinical trial , 2005, Cancer.
[88] G. Giaccone,et al. Phase III study of adjuvant vaccination with Bec2/bacille Calmette-Guerin in responding patients with limited-disease small-cell lung cancer (European Organisation for Research and Treatment of Cancer 08971-08971B; Silva Study). , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[89] M. Hidalgo,et al. A randomized, phase II ECOG trial of two dose levels of temsirolimus (CCI-779) in patients with extensive stage small cell lung cancer in remission after induction chemotherapy. A preliminary report , 2005 .
[90] M. Kris,et al. Imatinib mesylate lacks activity in small cell lung carcinoma expressing c‐kit protein , 2005, Cancer.
[91] F. DeMayo,et al. Genetically engineered mouse models for lung cancer , 2005 .
[92] U. Pastorino,et al. Detection of Overexpressed and Phosphorylated Wild-Type Kit Receptor in Surgical Specimens of Small Cell Lung Cancer , 2004, Clinical Cancer Research.
[93] M. Socinski,et al. Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[94] R. Mcgarry,et al. A meta-analysis of the timing of chest irradiation in the combined modality treatment of limited-stage small cell lung cancer. , 2004, The oncologist.
[95] P. Lambin,et al. Early versus late chest radiotherapy in patients with limited-stage small cell lung cancer , 2004 .
[96] F. Khuri,et al. Phase II study of the farnesyl transferase inhibitor R115777 in patients with sensitive relapse small-cell lung cancer. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.
[97] P. Lambin,et al. Early versus late chest radiotherapy for limited stage small cell lung cancer. , 2004, The Cochrane database of systematic reviews.
[98] J. Herman,et al. Generating mutations but providing chemosensitivity: the role of O6-methylguanine DNA methyltransferase in human cancer , 2004, Oncogene.
[99] D. Dunlop,et al. Phase II study of imatinib in patients with small cell lung cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[100] Michael F. Clarke,et al. Applying the principles of stem-cell biology to cancer , 2003, Nature Reviews Cancer.
[101] A. Berns,et al. Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. , 2003, Cancer cell.
[102] G. Giaccone,et al. Prospective, randomized, double-blind, placebo-controlled trial of marimastat after response to first-line chemotherapy in patients with small-cell lung cancer: a trial of the National Cancer Institute of Canada-Clinical Trials Group and the European Organization for Research and Treatment of Cancer , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[103] S. Gerson. Clinical relevance of MGMT in the treatment of cancer. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[104] J. Minna,et al. DNA methylation profiles of lung tumors. , 2001, Molecular cancer therapeutics.
[105] P. Gregory,et al. Histone acetylation and chromatin remodeling. , 2001, Experimental cell research.
[106] J. Minna,et al. Molecular genetics of small cell lung carcinoma. , 2001, Seminars in oncology.
[107] D. Smith,et al. Adjuvant and neoadjuvant therapy in prostate cancer. , 2001, Seminars in oncology.
[108] J P Pignon,et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. , 1999, The New England journal of medicine.
[109] K. Cantell,et al. Concomitant chemotherapy and IFN-alpha for small cell lung cancer: a randomized multicenter phase III study. , 1999, Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research.
[110] J. Carmichael,et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[111] R. Komaki,et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. , 1999, The New England journal of medicine.
[112] H. Satoh,et al. Lack of class II transactivator causes severe deficiency of HLA‐DR expression in small cell lung cancer , 1999, The Journal of pathology.
[113] G. Giaccone,et al. Role of recombinant interferon-gamma maintenance in responding patients with small cell lung cancer. A randomised phase III study of the EORTC Lung Cancer Cooperative Group. , 1997, European journal of cancer.
[114] N. Malats,et al. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[115] S. Baylin,et al. An achaete-scute homologue essential for neuroendocrine differentiation in the lung , 1997, Nature.
[116] S. Magdaleno,et al. Cyclin-dependent kinase inhibitor expression in pulmonary Clara cells transformed with SV40 large T antigen in transgenic mice. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.
[117] H. Hausmaninger,et al. Adjunctive interferon-α-2c in stage IIIb/Iv small-cell lung cancer : a phase III trial , 1997 .
[118] J. Crowley,et al. Role of recombinant interferon alfa-2a maintenance in patients with limited-stage small-cell lung cancer responding to concurrent chemoradiation: a Southwest Oncology Group study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[119] P Chomy,et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. , 1995, Journal of the National Cancer Institute.
[120] J. Jett,et al. Phase III trial of recombinant interferon gamma in complete responders with small-cell lung cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[121] J. Herndon,et al. Interleukin-2 activity in patients with extensive small-cell lung cancer: a phase II trial of Cancer and Leukemia Group B. , 1993, Journal of the National Cancer Institute.
[122] I. Kawase,et al. High Sensitivity to Peripheral Blood Lymphocytes and Low HLA‐class I Antigen Expression of Small Cell Lung Cancer Cell Lines with Diverse Chemo‐radiosensitivity , 1992, Japanese journal of cancer research : Gann.
[123] P. Leder,et al. SV40 T antigen transforms calcitonin cells of the thyroid but not CGRP-containing neurons in transgenic mice. , 1991, Oncogene.
[124] A. Okamoto,et al. Variable mutations of the RB gene in small-cell lung carcinoma. , 1990, Oncogene.
[125] G. Steele. Cancer: Principles and Practice of Oncology , 1983 .
[126] T. Shields,et al. The solitary pulmonary nodule. Ten-year follow-up of veterans administration-armed forces cooperative study. , 1975, Archives of surgery.
[127] S. Robinson,et al. Small Molecule Inhibitors of Aurora-A Induce Proteasomal Degradation of N-Myc in Childhood Neuroblastoma. , 2016, Cancer cell.
[128] Steven A. Roberts,et al. Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .
[129] Trevor J Pugh,et al. Mutational heterogeneity in cancer and the search for new cancer genes , 2014 .
[130] T. Lynch,et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[131] D. Nie,et al. Cancer stem cells and resistance to chemo and radio therapy. , 2012, Frontiers in bioscience.
[132] D. Ball,et al. Insights into the achaete-scute homolog-1 gene (hASH1) in normal and neoplastic human lung. , 2012, Lung cancer.
[133] A. Tsao. Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study , 2012 .
[134] A. Tsao. Randomized Phase II Study of Bevacizumab in Combination With Chemotherapy in Previously Untreated Extensive-Stage Small-Cell Lung Cancer: Results From the SALUTE Trial , 2011 .
[135] R. Weichselbaum,et al. Predictors of competing mortality in advanced head and neck cancer. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[136] S. Voelter-Mahlknecht,et al. The histone deacetylase inhibitor suberoylanilide hydroxamic acid down-regulates expression levels of Bcr-abl, c-Myc and HDAC3 in chronic myeloid leukemia cell lines. , 2005, International journal of molecular medicine.
[137] H. Hausmaninger,et al. Adjunctive interferon-alpha-2c in stage IIIB/IV small-cell lung cancer: a phase III trial. , 1997, European Respiratory Journal.
[138] K. Cantell,et al. Natural interferon alfa as maintenance therapy for small cell lung cancer. , 1992, European journal of cancer.
[139] H. Kreisman,et al. Small cell lung cancer presenting as a solitary pulmonary nodule. , 1990, Cancer.
[140] U. G. Dailey. Cancer,Facts and Figures about. , 2022, Journal of the National Medical Association.